Effect of BD 1047, a sigma(1) receptor antagonist, in the animal models predictive of antipsychotic activity.
Journal Title: Pharmacological Reports - Year 2006, Vol 58, Issue 5
Abstract
The sigma receptors were first classified as a subtype of opioid receptors but later they were found to be a distinct pharmacological entity. Many preclinical and clinical data have indicated that sigma receptor ligands have to be involved in neuropsychiatric disorders, including schizophrenia. Numerous data have suggested that potential antipsychotic activity of sigma ligands results from their "antagonistic" activity. However, the subcellular mechanisms by which sigma ligands exert their effects have not been elucidated in detail, therefore, the terms "agonist" or "antagonist" and their functional implications are not entirely unequivocal. The aim of the present study was to findout if BD 1047, described recently as a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia. In contrast to rimcazole and panamesine, two selective sigma ligands whose antipsychotic activity was confirmed clinically, BD 1047 did not decrease amphetamine-induced hyperactivity in mice in a statistically significant manner. Likewise, it did not modify the hyperactivity induced by NMDA receptor antagonists, phencyclidine, memantine or dizocilpine. On the other hand, BD 1047 attenuated apomorphine-induced climbing in mice and phencyclidine-induced head twitches in rats, like rimcazole and panamesine did. Summing up, BD 1047 shows a moderate activity in models used in this study suggesting that its usefulness as an antipsychtic drug is doubtful. However, more detailed studies are required for definitive confirmation of this conclusion.
Authors and Affiliations
Grażyna Skuza, Zofia Rogóż
Keywords
Related Articles
- EP ID EP123597
- DOI -
- Views 67
- Downloads 0
Synergism between dexketoprofen and meloxicam in an orofacial formalin test was not modified by opioid antagonists.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs for the management of acute and chronic pain. The role of the opioid system in the synergism between NSAIDs is not well characterized. M...
Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'.
Transforming growth factor beta (TGF-beta) is a cytokine engaged in a wide range of diverse and often contradictory functions. Its effect on the cardiovascular system is also ambiguous; on the one hand, there is a strong...
7-Nitroindazole enhances dose-dependently the anticonvulsant activities of conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model.
7-Nitroindazole (7NI, a nitric oxide synthase [NOS] inhibitor) administered intraperitoneally (ip), 30 min before the test, at doses ranging between 50-200 mg/kg, raised the threshold for electroconvulsions in mice. Line...
Molecular determinants of heart failure with normal left ventricular ejection fraction.
In population-based studies, heart failure with normal left ventricular (LV) ejection fraction (HFNEF) is now increasingly recognized and referred to as diastolic heart failure. However, the pathogenic mechanisms underly...
Impact of hypercholesterolemia on toxicity of N-nitrosodiethylamine: biochemical and histopathological effects.
N-nitrosodiethylamine (NDEA) is an important carcinogen frequently present in human environment and food chain. Nitrosamines such as NDEA produce oxidative stress due to generation of reactive oxygen species and alter th...